ArticleBMC neurology2026
Comprehensive characterization and prognostic analysis of multifocal intracranial germ cell tumors.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiven the limited evidence on multifocal intracranial germ cell tumors (iGCTs)-a rare but clinically distinct entity-this study comprehensively characterizes their clinical features and identifies key prognostic factors.
methodsA retrospective analysis was conducted on 48 patients diagnosed with multifocal iGCTs from 2006 to 2025 in our center. Demographics, clinical presentation, MRI characteristics, pathology, treatment modalities, and survival outcomes were analyzed. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-Meier methods. Prognostic factors were identified through univariate and multivariate analyses.
resultsMedian age at diagnosis was 13 years (range: 6-31), with male predominance (87.5%). The most common symptoms were diabetes insipidus (81.2%) and hemiparesis (56.2%). Significant imaging features included hemiatrophy (47.9%) and heterogeneous enhancement (68.8%). Germinoma was diagnosed in 66.7% of patients and combined chemoradiotherapy (CHT + RT) was administered to 58.3% of patients. The 10-year OS and PFS rates were 84.6% and 70.6%, respectively. In this exploratory analysis, factors associated with favorable outcomes included germinoma histology (HR = 0.06, 95% CI 0.01-0.53, P = 0.011), combined CHT + RT (HR = 0.09, 95% CI 0.01-0.76, P = 0.027), and absence of tumor-infiltrating lymphocytes (HR = 0.14, 95% CI 0.02-1.06, P = 0.050 for PFS).
conclusionMultifocal iGCTs represent a distinct clinical entity with outcomes that are poorer compared to solitary iGCTs. Germinoma, combined chemoradiotherapy, and lymphocyte infiltration may be associated with survival, warranting further investigation. These findings emphasize the importance of histology-driven, multimodal treatment strategies for optimizing outcomes in this rare disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.